WHO Pharmaceuticals Newsletter 2003, No. 04
(2003; 13 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentATYPICAL ANTI-PSYCHOTICS - Reports of hypertension
Afficher le documentBOTULINUM A - Patients misled over safety
Afficher le documentCHELIDONIUM MAJUS - Statement to advise use under supervision
Afficher le documentCYCLO-OXYGENASE (COX)-2 INHIBITORS - Reports of hepatotoxicity
Afficher le documentETONOGESTREL - Vaginal bleeding with sub-dermal implant
Afficher le documentFLUTICASONE - ADR update
Afficher le documentGATIFLOXACIN - Reports of abnormal glucose metabolism
Afficher le documentHORMONE REPLACEMENT THERAPY (HRT) - ‘Million Women Study’ confirms breast cancer association
Afficher le documentMEDROXY-PROGESTERONE - Reports of contraception failure with depot preparations
Afficher le documentMEFLOQUINE - Patient guide warns of psychiatric adverse events
Afficher le documentMETHOTREXATE - New solutions to prevent fatalities/adverse events
Afficher le documentMINOCYCLINE - Hepatic reactions
Afficher le documentPIPERACILLIN - Serum methotrexate monitoring advised during concomitant therapy
Afficher le documentRIFAMPICIN & PYRAZINAMIDE - Warning against use in latent tuberculosis
Afficher le documentSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs): Reports of hyponatraemia
Afficher le documentSIBUTRAMINE - Serotonin syndrome
Afficher le documentTICLOPIDINE - No decrease in ADR reports
Afficher le documentVIGA/VIGA FOR WOMEN - Presence of sildenafil
Afficher le documentWARFARIN & MICONAZOLE - Reminder about interaction
Ouvrir ce répertoire et afficher son contenuDRUGS IN THE NEWS
 

ETONOGESTREL - Vaginal bleeding with sub-dermal implant

Australia. Since August 2001, the Adverse Drug Reactions Advisory Committee (ADRAC) has received 130 reports of adverse reactions associated with the sub-dermal etonogestrel contraceptive implant (Implanon). Thirty-seven of the reports described prolonged vaginal bleeding of 2-26 weeks duration (median 8 weeks) which generally started soon after insertion, but in some cases after up to 16 weeks. Thirty-three of the 37 cases required removal of the implant; one patient was hospitalised and required 4 units of packed RBCs. The Committee notes that, in a published 3-year study of sub-dermal etonogestrel implant (Implanon), heavy or prolonged bleeding was experienced by 2.8% of patients.

Reports in WHO-file:

Vaginal haemorrhage 65

Reference:

Australian Adverse Drug Reactions Bulletin 22: 11-12, Jun 2003.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013